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The possible bioterrorism threat using the variola virus, the causative agent of smallpox, has promoted us to further investigate
the immunogenicity profiles of existing vaccines. Here, we study for the first time the immunogenicity profile of a replication-
competent smallpox vaccine (vaccinia Tiantan, VTT strain) for inducing neutralizing antibodies (Nabs) through mucosal
vaccination, which is noninvasive and has a critical implication for massive vaccination programs. Four different routes of
vaccination were tested in parallel including intramuscular (i.m.), intranasal (i.n.), oral (i.o.), and subcutaneous (s.c.) inoculations
in mice. We found that one time vaccination with an optimal dose of VTT was able to induce anti-VTT Nabs via each of the four
routes. Higher levels of antiviral Nabs, however, were induced via the i.n. and i.o. inoculations when compared with the i.m. and
s.c. routes. Moreover, the i.n. and i.o. vaccinations also induced higher sustained levels of Nabs overtime, which conferred better
protections against homologous or alternating mucosal routes of viral challenges six months post vaccination. The VTT-induced
immunity via all four routes, however, was partially effective against the intramuscular viral challenge. Our data have implications
for understanding the potential application of mucosal smallpox vaccination and for developing VTT-based vaccines to overcome
preexisting antivaccinia immunity.
1. Introduction
Smallpox, which was caused by infection with the variola
virus, was one of the most deadly diseases in human history
with a mortality rate of up to 50% [1, 2]. Fortunately, this
disease was completely eradicated throughout the world by
1980 after the introduction of a global smallpox vaccination
campaign [3]. During this process, vaccinia virus, which
shares broad antigenic properties with the variola virus,
played an essential role as an effective vaccine in inducing
protective immunity against smallpox [3–5]. It is well
accepted that vaccine-induced neutralizing antibodies are
critical to protection [6–8]. The fear of variola virus being
deliberately released in potential bioterrorism attacks and
the increasing use of vaccinia as vaccine vectors for other
diseases such as AIDS have led to more recent studies aimed
at understanding the protective immune responses induced
by the smallpox vaccine [9, 10]. It is, therefore, necessary
to investigate the neutralizing antibody responses induced
by historically used smallpox vaccines via different route of
vaccination.
The most extensively used smallpox vaccine in China was
the vaccinia virus Tiantan (VTT) strain [11]. Accordingly,
the original VTT was isolated from the skin lesion of a
smallpox patient in China around 1926 followed by extensive
passages of 3 times in monkeys, 5 in rabbits, 3 in bovines,
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then twice in rabbits and 3 times in bovines, repeatedly [12,
13]. Genetic analysis of VTT genome, however, suggested
that it is a vaccinia strain instead of a variola viral variant
[14]. The clinical safety of this vaccine has not been clearly
documented although VTT was historically used for millions
of people. These issues are essential for a safe smallpox
vaccine [15]. The biological characteristics of VTT have been
described in our recent studies [16, 17]. It was reported that
VTT caused larger lesions after intradermal vaccination and
was likely more virulent than other widely used smallpox
vaccines such as Lister or Wyeth [12, 18]. To date, whether
or not VTT can induce protective neutralizing antibody
responses through noninvasive mucosal vaccination remains
less understood [19, 20].
Here, we study VTT to investigate its immunogenicity
in terms of inducing neutralizing antibodies through four
different routes of vaccination in a mouse model, which
has not been previously studied. Moreover, by conducting
homologous and heterologous routes of viral challenges,
we aimed to determine the efficacy of VTT for protection
and to identify a strategy to overcome preexisting immu-
nity to VTT-based vaccines. This study involved a safe,
nonpathogenic viral challenge model using a high dose of
modified VTT, namely, MVTT-S, which expresses the spike
(S) glycoprotein of SARS-CoV. Since S is not expressed on
the surface of vaccinia virus, we aimed to determine the
role of anti-VTT neutralizing antibody (Nab) responses in
achieving protection by evaluating the seroconversion to S.
Our results have implications for understanding an aspect
of vaccinia-induced protective immunity and for developing
vaccinia-based vaccines.
2. Materials and Methods
2.1. Virus Stock and Cell Line. The background and bio-
logical properties of the smallpox vaccine vaccinia Tiantan
(VTT) have been described previously [16]. VTT stocks were
propagated in Vero cells and then purified by repeated freez-
ing and thawing and centrifugation through a 36% sucrose
cushion. The viral pellet was subjected to a sucrose gradient
centrifugation. Purified viruses were collected and studied
[21]. The plaque forming unit (PFU) of viral stocks was
titrated on Vero cells by a plaque-forming assay using crystal
violet staining. The construction and characterization of
the challenge virus MVTT-S have been described previously
[17].
2.2. Immunization of Mice. Five groups of female BALB/c
mice were included in the study. Each group of nine mice was
inoculated with an optimal dose of 106 PFU VTT through
one of four different routes including intramuscular (i.m.),
intranasal (i.n.), oral (i.o.), and subcutaneous (s.c.) inocula-
tions, respectively, [17]. Another group of nine mice received
a placebo as controls. Tomeasure lasting Nab responses, mice
were kept for six months for observation and testing.
2.3. Viral Challenge of VTT-Immunized Mice. After six
months of observation, each group of mice was further
divided into three subgroups. Each subgroup of three mice
was challenged with a dose of 2 × 106 PFU MVTT-S
through one of three different routes including i.m., i.n.,
and i.o., respectively. It is the highest dose possible for
mucosal challenge based on the concentration of our viral
stocks and the size of animals. After a three-week interval,
all animals were challenged again with the same dose of
2 × 106 PFU MVTT-S. Blood samples were collected on
week 3, week 26, week 29, and week 32 for measuring Nab
responses after MVTT-S challenge. Our animal protocols
were approved by the Institutional Committee on Laboratory
Animal Use of Wuhan University. Since MVTT-S is an
attenuated VTT variant which is not lethal in mice, we
define the full protection by the lack of detectable anti-S
Nab response induced by the challenge virus MVTT-S in this
study.
2.4. Anti-S Neutralizing Assay. A pseudovirus-based neu-
tralization assay was applied to determine the humoral
immune responses against the S glycoprotein of SARS-CoV
[22]. The pseudotype virus was generated by cotransfecting
293T cells with two plasmids pcDNA-Sopt9 and pNL4-
3Luc+Env−Vpr− carrying the optimized S gene and a
human immunodeficiency virus type 1 backbone, respec-
tively. For each experiment, pooled sera, which contain an
equal amount of serum of each vaccinated mouse in each
group, were subjected to the assay as described by others [23].
Luciferase activity was measured by the PerkinElmer Victor
Microplate Reader according to manufacturer’s instruction.
In comparison to serum samples of unvaccinated mice in
the same experiments, we score seropositive when an IC50
value reaches a serum dilution factor of 1 : 30. An IC50
value is a serum dilution factor that achieves 50% of viral
inhibition.
2.5. Anti-VTT Neutralizing Assay. To test the serum neu-
tralization activity against VTT, we used a flow-cytometry-
based assay similar to a previously published method [24].
For this assay, a modified VTT that contains a GFP (MVTT-
GFP) expression cassette was constructed [14]. Briefly, the
neutralizing activity of heat-inactivated sera (56◦C, 30min)
was determined by mixing 1.25 × 106 PFU/mL of VTT-
GFP virus in 20 µL with an equal amount of diluted serum
at 37◦C, for 1 h. After the incubation, 60 µL of the 293T
cells were added into each well of the plate and incubated
at 37◦C. 293T cells were diluted into 2.5 × 106/mL using
culture medium containing 10% FBS, 1% streptomycin
and penicillin, and 44 µg of cytosine arabinoside per mL.
After 24 hr incubation, the infected cells were washed with
PBS twice and then trypsinized (50 µL/well trypsin). The
cells were pelleted, washed, and then fixed with 200 µL
of 2% paraformaldehyde, and subsequently subjected to
the FACS analysis. The titer of viral neutralization was
determined by calculating the percent reduction of infected
cells showing GFP positive expression. Similarly, an IC50
value is a serum dilution factor that achieves 50% of viral
inhibition.
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2.6. Statistical Analyses. The Student’s t-test was used to
evaluate the statistical significance of Nab titers among
various groups of animals. The Origin 8 computer software
was used for this analysis.
3. Results
3.1. Higher Levels of Anti-VTT Nabs Were Induced via the
i.n. and i.o. Inoculations When Compared with the i.m. and
s.c. Routes. In this study, we sought to determine whether
VTT would induce different levels of Nabs via various
routes of vaccination. This is a critical question because
VTT was historically used as a smallpox vaccine for millions
of people yet its potential use as a noninvasive vaccine
remains elusive. To address this question, four groups of
mice were inoculated with an optimal dose of 106 PFU
VTT via s.c, i.m., i.n., and i.o. routes, respectively. Another
group of mice received a placebo as controls. Three weeks
after inoculation, the animals were tested for the production
of anti-VTT Nabs using a newly developed FACS-based
MVTT-GFP neutralization assay (Figure 1(a)) [24]. Since
the sample quantity is small, pooled sera were tested for
each experimental group. The pooled sera contain an equal
amount of serum of individualmice in each group. We found
that each route of vaccination was able to induce anti-VTT
Nab responses after one-time vaccination (Figure 1(b)). The
levels of anti-VTT Nabs, however, varied depending on the
route of vaccination. Apparently, higher levels of Nabs were
induced via the i.n. and i.o. inoculations when compared
with the i.m. and s.c. routes. The serumdilution factors based
on the IC50 value via the different routes (i.n., i.o., i.m., and
s.c.) were 1 : 711, 1 : 2370, 1 : 428, and 1 : 32, respectively.
3.2. Mucosal Vaccination Also Induced Higher Sustained Levels
of Nabs over time. In order to measure the long-lasting
levels of Nabs generated, we kept separate groups of the
vaccinated animals for six months. Despite the virulent
effects of VTT (e.g., body weight changes) during the
acute phase of vaccination, all mice survived for continuous
observation. After six months of the vaccination, serum
samples were collected and subsequently subjected to the
same neutralization assay. Interestingly, although the IC50
was not significantly improved for the i.o. group, the rest
of three groups of mice, especially the i.n. group, developed
higher levels of lasting antivaccinia Nabs when compared
to the early time point (Figures 1(b) and 1(c)), suggesting
a prolonged VTT-antigen stimulation to immune system.
The serum dilution factors based on the IC50 value via the
different routes (i.n. and i.o. versus i.m. and s.c.) were 1 : 2265
and 1 : 2397 (average 1 : 2331) versus 1 : 671 and 1 : 387
(average 1 : 529), respectively (Table 1). Furthermore, higher
levels of long-lasting antivaccinia Nabs were consistently
found in the i.n. and i.o. groups when compared with the
i.m. and s.c. groups (Figure 1(c)). The average IC50 value of
mucosal groups (i.n. and i.o.) is about 4.4-fold higher than
that of i.m. and s.c routes (1 : 2331 versus 1 : 529, P < .01).
Randomly selected individualmice of each group were tested
with consistent results obtained.
3.3. Protection against Homologous Routes of Mucosal MVTT-
S Challenges. To determine the long-lasting efficacy of the
four routes of VTT vaccination in parallel, ten groups of
vaccinated mice were challenged with MVTT-S six months
after the vaccination. Each mouse received 2 × 106 PFU
of MVTT-S, the highest possible dose based on our viral
stocks, via the i.n. or i.o. routes, respectively, which mimic
the natural transmission of the variola virus. Since no anti-
S antibodies were detected three weeks after challenge in all
groups, we subsequently gave another MVTT-S challenge at
the same dose in the same way. We found that i.o. and i.n.
VTT vaccinations protected mice significantly against the
homologous i.o. and i.n. MVTT-S challenges, respectively,
without anti-S antibodies detected after the second challenge
(Figure 2(a) and Table 1). The lack of seroconversion to
S serves as a biomarker of the protection against MVTT-S
infection.
3.4. Protection against Alternating Routes of Mucosal MVTT-
S Challenges. We then analyzed other groups of animals.
We found that i.o. and i.n. VTT vaccinations protected
mice completely against heterologous routes of i.n. and
i.o. MVTT-S challenges, respectively, without any detectable
anti-S Nabs (Figure 2(a)). In contrast, MVTT-S challenges
resulted in high levels of anti-S Nabs in VTT-naı¨ve or
nonvaccinated mice after the second challenge (Figure 2(a)).
The IC50 values reached over 1 : 10,000 serum dilution titer.
Moreover, i.m. VTT vaccination also protected mice com-
pletely against i.n. and i.o. MVTT-S challenges, respectively
(Figure 2(a)). Here, the lack of detectable anti-S Nabs after
two consecutiveMVTT-S challenges likely suggests a possible
complete protection (Figure 2(a)). Notably, the s.c. VTT
vaccination did not completely protect mice against i.n. or
i.o. MVTT-S challenges as anti-S antibodies were readily
detected three weeks after the second challenge (Figure 2(b)).
Since the mean anti-S IC50 titer of all s.c. vaccinated mice was
significantly lower than that of all nonvaccinated controls
(1 : 1778 versus 1 : 14678, P = .03) (Figures 2(a) and 2(b)),
we speculated that at least partial significant protection was
achieved by the s.c. VTT vaccination. This P = .03 value
was determined by comparing the anti-S mean value of the
s.c. vaccinated group (1 : 1598, 1 : 1026, and 1 : 2710, with
an average value of 1 : 1778) versus control group (1 : 14261,
1 : 8251, and 1 : 21523, with an average value of 1 : 14678).
It is possible that the less protection of s.c. vaccinated
mice is related to lower levels of anti-VTT neutralizing
antibodies induced (Figure 1(a) and Table 1). Since MVTT-S
causes transient viremia and infection in mice as we recently
described [19], our efforts to detect live challenge virus
around three weeks after each challenge in all groups were
unsuccessful.
3.5. Lack of Complete Protection against Intramuscular
MVTT-S Challenges. Since mucosal VTT vaccination indu-
ced likely full protection against homologous and heterol-
ogous routes of mucosal MVTT-S challenges (Figure 2(a)),
we sought to determine whether the protection would
apply to a systemic route of viral challenge. For this
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Figure 1: Anti-VTT neutralizing antibody responses after the VTT vaccination. (a) A FACS-based neutralization assay was newly developed
to measure the anti-VTT neutralizing antibody responses. (b) Serum samples were tested three weeks after the VTT vaccination. (c) Serum
samples were tested six months after the VTT vaccination. Due to a limited amount of serum collected from each mouse, pooled sera, which
contain an equal amount of serum of each vaccinated mouse in each group, were subjected to each experiment. The X-axis represents the
serum dilution factor whereas the Y -axis indicates the percentage of viral inhibition. An IC50 value is a serum dilution factor which achieves
50% of viral inhibition as indicated by the dashed horizontal line. The experiment was repeated twice with similar results obtained. Placebo
(no VTT) mice were tested as well.
Table 1: Neutralizing antibody titer from different time points after VTT vaccination and MVTT-S Challenges.
Groups i.m. i.n. i.o. s.c. placebo
Vaccination
VTT (3 weeks)
VTT (6 months)
NA
NA
428
671
NA
NA
711
2265
NA
NA
2370
2397
NA
NA
32
387
NA
NA
ND
ND
MVTT-S Challenge
i.m. (1st)
i.m. (2nd)
i.n. (1st)
i.n. (2nd)
i.o. (1st)
i.o. (2nd)
ND
2732
ND
ND
ND
ND
3288
6280
2065
1587
4555
2362
ND
9369
ND
ND
ND
ND
5249
5210
5141
2944
4937
5148
ND
936
ND
ND
ND
ND
4742
4721
6838
6205
2601
4901
ND
1598
ND
1026
ND
2710
333
1386
520
350
35
221
ND
14261
ND
8251
ND
21523
46
718
349
1004
101
1014
The values of anti-S IC50 are in bold whereas the values of anti-VTT IC50 are not. NA: not applied; ND: not detected.
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Figure 2: Anti-S neutralizing antibody responses in VTT-vaccinated mice after two MVTT-S challenges. (a) Serum samples of i.m., i.n.,
and i.o. VTT-vaccinated as well as of placebo-inoculated (no VTT) mice were tested. (b) Serum samples of s.c. VTT-vaccinated mice were
tested. Pooled sera, which contain an equal amount of serum of each vaccinated mouse in each group, were subjected to each experiment.
The X-axis represents the serum dilution factor whereas the Y -axis indicated the percentage of viral inhibition. The dashed horizontal line
indicates IC50 values. The experiment was repeated twice with similar results obtained.
purpose, another three groups of VTT-vaccinated mice were
challenged with MVTT-S via the i.m. route also at six
months postvaccination. Similarly, no detectable levels of
anti-S Nabs were found three weeks after the first MVTT-
S challenge, suggesting a protective role of VTT-induced
immunity. However, we found that the second MVTT-S
challenge was able to generate substantial levels of anti-S
Nabs in all three groups (Figure 3). Since the levels of anti-
S Nabs (both IC90 and IC50 values) were lower in three
vaccinated groups compared to the placebo nonvaccinated
group, it is likely that i.m., i.n., and i.o. vaccination conferred
partial significant protection against MVTT-S challenges. For
example, the serum dilution factors based on the IC50 value
via different routes of prevaccination (placebo > i.n., i.o., or
i.m.) were 1 : 14261 > 1 : 9369, 1 : 936, or 1 : 2732, respectively
(Table 1 and Figure 3).
Since substantial levels of anti-VTT Nab responses were
induced by a one time VTT vaccination via four different
routes (Figure 1(b)), it was puzzling why these Nabs were
not able to block i.m. MVTT-S infections completely. For
this reason, we speculated that there might be a difference
in the recalled anti-VTT Nab responses after the MVTT-
S challenges. Therefore, we measured the levels of anti-
VTT Nab responses after each of the two MVTT-S chal-
lenges. We found that the first MVTT-S challenge boosted
the levels of anti-VTT Nabs significantly, confirming its
shared neutralizing determinants with VTT (Figure 4(a)).
The average serum dilution factor of antivaccinia Nabs
among i.m., i.n., and i.o. VTT-vaccinated mice had reached
0
10
20
30
40
50
60
70
80
90
100
In
h
ib
it
io
n
(%
)
Serum dilution factor
No VTT/i.m.MVTT-S×2
i.m.VTT/i.m.MVTT-S×2
i.n. VTT/i.m.MVTT-S×2
i.o. VTT/i.m.MVTT-S×2
100 1000 10000
Figure 3: Anti-S neutralizing antibody responses in VTT-vaccinat-
ed mice after two i.m.MVTT-S challenges. Serum samples collected
three weeks after the second MVTT-S challenge were tested in
this experiment. Pooled sera, which contain an equal amount of
serum of each vaccinated mouse in each group, were subjected to
each experiment. The X-axis represents the serum dilution factor
whereas the Y -axis indicated the percentage of viral inhibition. The
dashed horizontal line indicates IC50 values. The experiment was
repeated twice with similar results obtained. As controls, no VTT
represents mice, who did not receive VTT-vaccination.
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Figure 4: Anti-VTT neutralizing antibody responses after the first
(a) and the second (b)MVTT-S challenges. Serum samples collected
three weeks after each of the two MVTT-S challenges were included
in this experiment. Pooled sera, which contain an equal amount of
serum of each vaccinated mouse in each group, were subjected to
each experiment. The X-axis represents the serum dilution factor
whereas the Y -axis indicates the percentage of viral inhibition. The
dashed horizontal line indicates IC50 values. The experiment was
repeated twice with similar results obtained. As controls, no VTT
represents mice, who did not receive VTT-vaccination.
comparable levels with IC50 values of 1 : 3303, 1 : 5109, and
1 : 4727, respectively, which is not statistically significant
(Figure 4(a)). This P value was calculated from the average
values of anti-VTT Nabs after the first challenge from three
groups: i.m. (1 : 3288, 1 : 2065, and 1 : 4555, with an average
of 1 : 3303), i.n. (1 : 5249, 1 : 5141, and 1 : 4937, with an
average of 1 : 5109), and i.o. (1 : 4742, 1 : 6838, 1 : 2601, with
an average of 1 : 4727). In addition, we determined the anti-
VTT Nab response after the second challenge of MVTT-
S. We found that the average serum dilution titer of anti-
VTT Nabs among i.m., i.n., and i.o. pre-VTT-vaccinated
mice had likely saturated at comparable levels with the IC50
values of 1 : 3410, 1 : 4434, and 1 : 5276, respectively, which
is not statistically significant (Figure 4(b)). This P value was
calculated from the average values of anti-VTT Nabs after the
second challenge from three groups: i.m. (1 : 6280, 1 : 1587,
and 1 : 2362, with an average of 1 : 3410), i.n. (1 : 5210,
1 : 2944, and 1 : 5148, with an average of 1 : 4434), and i.o.
(1 : 4721, 1 : 6205, and 1 : 4901, with an average of 1 : 5276).
Apparently, these levels of the recalled anti-VTT Nabs were
sufficient to block completely the mucosal (i.n. and i.o.)
but not the systemic (i.m.) MVTT-S challenges, suggesting
a likely difference between mucosal and systemic immunity.
4. Discussion
The smallpox vaccination, which involves live vaccinia virus,
remains a gold standard of vaccines because it has led to
the complete eradication of a deadly human viral disease. To
our knowledge, this study is the first to provide a parallel
experimental comparison of four different routes of VTT
vaccination for inducing protective efficacy in a mouse
model. We provide evidence that one-time vaccination with
VTT through each of four different routes was able to induce
long-lasting antivaccinia Nab responses in mice. Apparently,
higher levels (4.4-fold) of the Nab responses were induced
via the mucosal i.n. and i.o. inoculations when compared
with the i.m. and s.c. routes. Moreover, the i.n. and i.o. VTT
vaccination likely protected animals completely from two
consecutive mucosal challenges of the MVTT-S strain via
either homologous (i.n. and i.o.) or heterologous (i.o. and
i.n.) routes, respectively, (Figure 2(a)). As controls, s.c. VTT
vaccination did not achieve full protection against i.m., i.n.,
or i.o. MVTT-S challenges, respectively, (Figure 2(b)). While
i.m. VTT vaccination fully protected animals from i.n. and
i.o. MVTT-S challenges, i.m., i.n., and i.o. VTT-vaccinated
animals were not fully protected from i.m. challenges (Fig-
ures 2(a) and 3). Our results, therefore, suggested that the
route of VTT vaccination is critical for inducing protection
in mice. In the meantime, the finding that i.m. MVTT-
S challenge overcomes preexisting antivaccinia immunity
induced via mucosal routes has implications for MVTT-
based mucosal vaccine development.
The route of VTT vaccination determines the level
of long-lasting antivaccinia Nabs induced. It has been
demonstrated that Nabs induced by vaccinia vaccine play an
essential role in providing sterile immunity against smallpox
infections [25, 26]. Here we show that VTT displays an
advantage for inducing higher levels of antivaccinia Nabs
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through the noninvasive mucosal route of vaccination.
The underlying mechanism of this finding remains largely
unknown, although we have recently provided evidence that
the tissue tropism may play a role in affecting the immuno-
genicity of a vaccinia-based vaccine [19]. Since VTT and its
variants unlikely establish long-term persistent infection in
mice, mechanisms for the maintenance of immunological
memory for lasting Nabs remain to be further investigated
[8]. One study showed that antigen can be retained in
the draining lymph nodes for extended periods of time
[27]. Whether this finding would have implications for the
continuous maturation of VTT-induced Nabs observed in
our study will require future studies. We acknowledge that
different route of vaccination may have different protective
effects. We did not conduct a direct comparison between
intradermal (i.d.) vaccination with other routes because i.d.
vaccination did not seem to induce high levels of Nabs in
our previous studies [17]. We, however, will compare the
skin scarification vaccination with other routes in our future
studies as it conferred sterile protection in humans against
smallpox infection historically.
Traditional VV challenge models involved the use of
highly pathogenic and lethal dose viruses for challenges,
which require special biosafety containments. In this study,
we developed a convenient model for animal challenge based
on testing of the antibody response to the highly immuno-
genic S protein. Through our protocol, the preparation
of vaccinia virus was mostly intracellular mature virion
(IMV) particles. Since the S spike protein was not located
on the IMV by Western blot analysis (data not shown),
the MVTT-S particles themselves cannot induce S-specific
antibodies unless they enter the cells and initiate infection.
This design provides anti-S antibody as a valuable biological
indicator for protection of MVTT-S challenge in mice and
eliminates the biosafety issues related to the restricted use
of pathogenic vaccinia WR by laboratory regulations [28],
as well as helps to reduce study costs. Nonpathogenic viral
challenge model has previously been used to study the
neutralizing antibody-mediated protection against immun-
odeficiency viral infection [29]. We, however, recognize the
limitation of our experimental system because theremight be
major differences between lethal and nonpathogenic vaccinia
challenge systems. For example, NKT-cells, CD8+ CTLs
together with Nabs may be involved in protection against a
highly pathogenic virus [30]. This issue should be further
studied in future studies.
Mucosal VTT vaccination elicited protection against
both homologous and heterologous routes of mucosal
MVTT-S challenges. Our results have provided scientific
evidence that mucosal VTT vaccination (e.g., one time i.n.
or i.o. VTT vaccination in this study) likely confers complete
protection against mucosal routes of viral challenges
(Figure 2(a)), which is consistent to previous findings
[14, 31]. These findings are relevant to smallpox prevention
because the vaccination likely provided a protective barrier
at the dominant portal of variola viral entry, in the mucosa.
This is concluded by the fact that the transmission of
smallpox occurs mainly through inhalation of airborne
variola virus, usually droplets expressed from the oral, nasal,
or pharyngeal mucosa of an infected person [32]. Critically,
the role of mucosal immunization with a smallpox vaccine
has been demonstrated in previous studies [33, 34]. Since
four groups of mice all developed systemic antivaccinia Nabs
before MVTT-S challenges (Figure 1(c)), we speculated that
higher levels (4.4-fold) of the Nab responses induced via
the mucosal i.n. and i.o. inoculations compared with the
s.c. route might have played a role in blocking MVTT-S
challenge completely. To this end, the rapidly recalled high
levels of anti-VTT Nabs after the MVTT-S challenges might
also contribute to this protection (Figure 4(a)). In spite
of these findings, extra attentions should be paid when
VTT is used as a human smallpox vaccine for mucosal
vaccination due to (1) its in vivo toxicity or virulence [16] as
well as (2) its complicated quasispecies containing a group
of viral variants [14]. As a substitute, it is evident to use a
safely attenuated and homogenous MVTT strain to conduct
mucosal smallpox vaccinations [14].
One obstacle of the application of vaccinia-based vac-
cine is the preexisting antivector immunity [35]. This is
often an issue for the clinical development of a vaccinia-
based vaccine. Previous studies indicated that mucosal
vaccination overcomes preexisting antivaccinia immunity
generated through skin vaccination [35, 36]. Consistently,
we showed that i.n. or i.o. MVTT-S challenges overcame
preexisting antivaccinia immunity generated through s.c.
VTT vaccination for inducing anti-S Nabs (Figure 2(b)) [17].
Moreover, we now provide a new finding that i.m. MVTT-
S challenges overcome preexisting antivaccinia immunity
generated through s.c., i.n., or i.o. route of VTT vaccination
(Figures 2(a) and 3). Our findings have implications either
for overcoming the preexisting antivaccinia immunity or
for improving the immunogenicity of a vaccinia-based
vaccine. Since vaccinia-based vaccines have been developed
for inducing protective immune responses at the mucosal
sites of viral transmission for HIV and other pathogens [37–
39], our findings provide evidence to support a new strategy
of heterologous routes of prime and boost vaccination using
the same vaccine. In comparison to heterologous prime and
boost regimens using different viral vectors [40, 41], this is
an area of interest for further investigations.
One limitation of our study is the lack of measurements
of T-cell-mediated immunity. Besides Nabs, it is possible
that the observed VTT-induced protection was partially
contributed by cell-mediated immunity. To this end, the
mucosal route of vaccination may also be crucial for the
generation of highly protective T-cell-mediated immunity.
A recent study demonstrated that protection against lethal
respiratory vaccinia challenge requires both respiratory
mucosal TEM cells and central memory T cells [42]. A
future study is, therefore, necessary to address the protective
effects of specific cell-mediated immunity under the similar
experimental conditions.
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